DISEASE INDICATIONS: Atopic Dermatitis
MANUFACTURER: Leo Pharma
USAGE: Subcutaneous
MEDICINE APPROVED BY:
Food and Drug Administration (FDA)
Adbry (tralokinumab-ldrm) is a fully human monoclonal antibody that neutralizes the activity of interleukin-13 (IL-13), a cytokine that plays a key role in the pathogenesis of atopic dermatitis. Adbry is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years of age and older.
